12 unchanged sentences
333-217245), filed with the Commission on April 10, 2017).
+Added: Collaboration and License Agreement, by and between the Company and Angelini Pharma Rare Diseases AG, dated July 9, 2020.
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
OVID THERAPEUTICS INC.
−Removed: August 10, 2020
+Added: November 12, 2020
/s/ Jeremy M.
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 10, 2020
+Added: November 12, 2020
/s/ Timothy Daly
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.